Trade Harrow Health, Inc. - HROW CFD

Add to favourite

9.27

1.09%

View detailed chart

0.11

Low: 9.01

High: 9.3

Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow
Ownership

Trading Conditions

Spread

0.11

Long position overnight fee

-0.026235%

Short position overnight fee

0.004012%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Harrow Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	9.17
Open*	9.06
1-Year Change*	-18.01%
Day's Range*	9.01 - 9.3
52 wk Range	7.60-28.25
Average Volume (10 days)	1.70M
Average Volume (3 months)	14.45M
Market Cap	323.79M
P/E Ratio	-100.00K
Shares Outstanding	35.12M
Revenue	114.17M
EPS	-0.45
Dividend (Yield %)	N/A
Beta	0.30
Next Earnings Date	Mar 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Dec 1, 2023	9.27	0.15	1.64%	9.12	9.31	9.00
Nov 30, 2023	9.17	0.21	2.34%	8.96	9.31	8.81
Nov 29, 2023	8.94	-0.03	-0.33%	8.97	9.41	8.92
Nov 28, 2023	8.95	-0.01	-0.11%	8.96	9.06	8.68
Nov 27, 2023	9.06	-0.23	-2.48%	9.29	9.46	8.94
Nov 24, 2023	9.33	0.22	2.41%	9.11	9.39	9.11
Nov 22, 2023	9.14	0.06	0.66%	9.08	9.30	9.01
Nov 21, 2023	9.17	-0.29	-3.07%	9.46	9.62	9.05
Nov 20, 2023	9.41	0.46	5.14%	8.95	9.48	8.87
Nov 17, 2023	8.91	0.25	2.89%	8.66	8.91	8.21
Nov 16, 2023	8.56	0.59	7.40%	7.97	8.77	7.97
Nov 15, 2023	8.04	0.02	0.25%	8.02	8.48	7.76
Nov 14, 2023	8.15	-1.61	-16.50%	9.76	9.82	7.56
Nov 13, 2023	12.80	0.33	2.65%	12.47	12.94	12.47
Nov 10, 2023	12.77	0.25	2.00%	12.52	12.82	12.23
Nov 9, 2023	12.77	-0.12	-0.93%	12.89	12.98	12.51
Nov 8, 2023	12.89	-0.35	-2.64%	13.24	13.49	12.83
Nov 7, 2023	13.23	-0.12	-0.90%	13.35	13.36	13.11
Nov 6, 2023	13.34	-0.63	-4.51%	13.97	14.01	13.28
Nov 3, 2023	14.21	0.54	3.95%	13.67	14.45	13.67

Harrow Health, Inc. Events

Time (UTC)	Country	Event
Thursday, March 21, 2024
Time (UTC) 10:59	Country US	Event Q4 2023 Harrow Inc Earnings Release Q4 2023 Harrow Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	88.595	72.476	48.871	51.165	41.372
Revenue	88.595	72.476	48.871	51.165	41.372
Cost of Revenue, Total	25.383	18.214	14.463	16.749	16.521
Gross Profit	63.212	54.262	34.408	34.416	24.851
Total Operating Expense	86.676	69.501	48.559	55.968	46.486
Selling/General/Admin. Expenses, Total	58.243	41.315	31.247	33.096	29.243
Research & Development	3.05	11.084	2.413	2.083	0.825
Unusual Expense (Income)	0	-1.112	0.436	4.04	-0.103
Operating Income	1.919	2.975	0.312	-4.803	-5.114
Interest Income (Expense), Net Non-Operating	-21.291	-20.896	-3.727	4.048	20.132
Other, Net	0.102	0.047		0.63
Net Income Before Taxes	-14.011	-17.874	-3.415	-0.125	14.625
Net Income After Taxes	-14.086	-18.007	-3.419	-0.125	14.625
Net Income Before Extra. Items	-14.086	-18.007	-3.357	0.168	14.625
Net Income	-14.086	-18.007	-3.357	0.168	14.625
Income Available to Common Excl. Extra. Items	-14.086	-18.479	-3.357	0.168	14.625
Income Available to Common Incl. Extra. Items	-14.086	-18.479	-3.357	0.168	14.625
Diluted Net Income	-14.086	-18.479	-3.357	0.168	14.625
Diluted Weighted Average Shares	27.461	26.7575	25.8953	26.4661	23.812
Diluted EPS Excluding Extraordinary Items	-0.51295	-0.69061	-0.12964	0.00635	0.61418
Diluted Normalized EPS	-0.63743	-0.71762	-0.11869	0.159	0.62636
Gain (Loss) on Sale of Assets	5.259			0	-0.393
Minority Interest		0	0.062	0.293
Total Adjustments to Net Income	0	-0.472

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	33.47	26.103	20.329	22.823	23.323
Revenue	33.47	26.103	20.329	22.823	23.323
Cost of Revenue, Total	10	8.271	6.165	6.721	6.534
Gross Profit	23.47	17.832	14.164	16.102	16.789
Total Operating Expense	31.118	30.358	22.107	22.917	21.633
Selling/General/Admin. Expenses, Total	19.957	15.888	15.239	15.421	14.185
Research & Development	1.161	0.734	0.703	0.775	0.914
Unusual Expense (Income)	0	5.465	0		0
Operating Income	2.352	-4.255	-1.778	-0.094	1.69
Interest Income (Expense), Net Non-Operating	-6.418	-2.705	-2.528	-6.335	-7.889
Net Income Before Taxes	-4.244	-6.931	1.055	-6.429	-6.199
Net Income After Taxes	-4.229	-6.643	1.055	-6.464	-6.239
Minority Interest
Net Income Before Extra. Items	-4.229	-6.643	1.055	-6.464	-6.239
Net Income	-4.229	-6.643	1.055	-6.464	-6.239
Income Available to Common Excl. Extra. Items	-4.229	-6.643	1.055	-6.464	-6.239
Income Available to Common Incl. Extra. Items	-4.229	-6.643	1.055	-6.464	-6.239
Diluted Net Income	-4.229	-6.643	1.055	-6.464	-6.239
Diluted Weighted Average Shares	30.4587	30.2897	27.9626	27.3496	27.3035
Diluted EPS Excluding Extraordinary Items	-0.13884	-0.21932	0.03773	-0.23635	-0.22851
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.13884	-0.10204	-0.15034	-0.23635	-0.22851
Other, Net	-0.178	0.029	0.102		0
Total Adjustments to Net Income			0	0	0
Gain (Loss) on Sale of Assets			5.259

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	118.26	60.662	40.982	36.767	32.843
Cash and Short Term Investments	101.859	50.67	32.556	29.949	28.258
Cash & Equivalents	96.27	42.167	4.101	4.749	6.838
Total Receivables, Net	6.388	4.518	3.513	2.731	1.914
Accounts Receivable - Trade, Net	6.249	4.47	2.662	2.009	1.914
Total Inventory	6.541	4.217	3.962	3.301	1.834
Prepaid Expenses	3.354	1.165	0.561	0.481	0.837
Other Current Assets, Total	0.118	0.092	0.39	0.305
Total Assets	157.378	98.329	57.474	59.085	49.451
Property/Plant/Equipment, Total - Net	10.999	9.076	10.667	11.934	6.375
Goodwill, Net	0.332	0.332	0.332	0.332	2.227
Intangibles, Net	25.837	17.126	2.524	2.337	3.059
Total Current Liabilities	18.632	9.722	10.799	12.284	11.901
Payable/Accrued			-0.8	7.702	6.25
Accrued Expenses	12.079	4.524	3.982	2.746	2.283
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0	0.008	3.906	1.779	3.249
Other Current Liabilities, Total	0.113	0.016	0.066	0.057	0.119
Total Liabilities	129.783	87.043	30.291	31.374	24.7
Total Long Term Debt	104.174	71.664	12.395	12.245	11.999
Long Term Debt	104.174	71.654	12.378	12.219	11.999
Capital Lease Obligations	0	0.01	0.017	0.026	0
Deferred Income Tax
Other Liabilities, Total	7.332	6.012	7.452	7.138	0.8
Total Equity	27.595	11.286	27.183	27.711	24.751
Common Stock	0.03	0.027	0.026	0.026	0.024
Additional Paid-In Capital	137.058	106.666	104.557	101.728	98.938
Retained Earnings (Accumulated Deficit)	-109.493	-95.407	-77.4	-74.043	-74.211
Total Liabilities & Shareholders’ Equity	157.378	98.329	57.474	59.085	49.451
Total Common Shares Outstanding	29.9015	26.9028	25.7499	25.5269	24.3396
Property/Plant/Equipment, Total - Gross	20.06	16.909	17.053	17.328
Accumulated Depreciation, Total	-9.061	-7.833	-6.386	-5.394
Long Term Investments	0	11.133	2.969	7.715	4.947
Note Receivable - Long Term
Short Term Investments	5.589	8.503	28.455	25.2	21.42
Minority Interest	-0.355	-0.355	-0.355	-0.293
Accounts Payable	6.44	5.174	3.645
Other Long Term Assets, Total	1.95

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	110.278	60.296	51.687	118.26	64.074
Cash and Short Term Investments	73.875	29.671	26.879	101.859	49.121
Cash & Equivalents	65.61	22.754	19.248	96.27	44.959
Short Term Investments	8.265	6.917	7.631	5.589	4.162
Total Receivables, Net	18.696	18.986	12.309	6.388	6.882
Accounts Receivable - Trade, Net	18.468	18.258	12.111	6.249	6.743
Total Inventory	8.924	8.555	9.093	6.541	5.283
Prepaid Expenses	8.665	2.657	3.288	3.354	2.715
Other Current Assets, Total	0.118	0.427	0.118	0.118	0.073
Total Assets	286.065	223.989	217.498	157.378	98.992
Property/Plant/Equipment, Total - Net	10.601	10.789	10.922	10.999	10.979
Property/Plant/Equipment, Total - Gross	20.405	20.304	20.208	20.06	19.842
Accumulated Depreciation, Total	-9.804	-9.515	-9.286	-9.061	-8.863
Goodwill, Net	0.332	0.332	0.332	0.332	0.332
Intangibles, Net	164.854	152.284	154.269	25.837	21.51
Long Term Investments				0	2.097
Total Current Liabilities	19.029	23.011	17.708	18.632	18.371
Payable/Accrued					5.906
Accrued Expenses	11.63	12.373	11.404	12.079	5.307
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases				0
Other Current Liabilities, Total	1.374	0.132	0.067	0.113	0.115
Total Liabilities	210.308	201.582	195.615	129.783	97.775
Total Long Term Debt	182.186	169.712	168.85	104.174	72.239
Long Term Debt	182.186	169.712	168.85	104.174	72.239
Capital Lease Obligations				0
Minority Interest	-0.355	-0.355	-0.355	-0.355	-0.355
Other Liabilities, Total	9.448	9.214	9.412	7.332	7.52
Total Equity	75.757	22.407	21.883	27.595	1.217
Common Stock	0.035	0.03	0.03	0.03	0.027
Additional Paid-In Capital	200.478	142.742	137.989	137.058	111.738
Retained Earnings (Accumulated Deficit)	-124.756	-120.365	-116.136	-109.493	-110.548
Total Liabilities & Shareholders’ Equity	286.065	223.989	217.498	157.378	98.992
Total Common Shares Outstanding	35.1176	30.2769	30.0564	29.9015	27.0743
Accounts Payable	6.025	10.506	6.237	6.44	7.043
Other Long Term Assets, Total	0	0.288	0.288	1.95

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-14.086	-18.007	-3.419	-0.125	14.625
Cash From Operating Activities	1.705	5.082	-1.1	0.95	0.687
Cash From Operating Activities	1.477	1.717	1.88	1.936	1.608
Amortization	1.578	0.161	0.167	0.209	0.235
Non-Cash Items	18.304	21.464	6.541	0.653	-19.218
Cash Taxes Paid	0.075	0.011	0.004	0.017	0.004
Cash Interest Paid	6.48	4.823	1.791	1.967	2.097
Changes in Working Capital	-5.568	-0.253	-6.269	-1.723	3.437
Cash From Investing Activities	-1.743	-18.686	-0.981	-1.833	-2.199
Capital Expenditures	-2.597	-1.786	-0.862	-1.468	-1.768
Other Investing Cash Flow Items, Total	0.854	-16.9	-0.119	-0.365	-0.431
Cash From Financing Activities	54.141	51.47	1.433	-1.006	4.131
Financing Cash Flow Items	-0.876			-0.282	-0.053
Issuance (Retirement) of Stock, Net	23.297	-3.508	-0.029	0.769	4.875
Issuance (Retirement) of Debt, Net	31.72	55.105	1.462	-1.493	-0.691
Net Change in Cash	54.103	37.866	-0.648	-1.889	2.619
Deferred Taxes					0
Total Cash Dividends Paid	0	-0.127

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-6.643	-14.086	-15.141	-8.677	-2.438
Cash From Operating Activities	-8.214	1.705	5.417	5.827	0.967
Cash From Operating Activities	0.292	1.477	1.09	0.843	0.419
Amortization	2.207	1.578	1.2	0.802	0.404
Non-Cash Items	6.014	18.304	20.374	13.531	5.09
Cash Taxes Paid		0.075	0.075	-0.04	0
Cash Interest Paid	3.371	6.48	4.851	3.234	1.617
Changes in Working Capital	-9.796	-5.568	-2.106	-0.672	-2.508
Cash From Investing Activities	-130.97	-1.743	-1.738	-0.669	-0.41
Capital Expenditures	-0.496	-2.597	-1.719	-0.664	-0.404
Other Investing Cash Flow Items, Total	-130.474	0.854	-0.019	-0.005	-0.006
Cash From Financing Activities	62.162	54.141	-0.887	-0.887	-0.776
Issuance (Retirement) of Stock, Net	-0.513	23.297	0.007	0.007	-0.773
Issuance (Retirement) of Debt, Net	62.675	31.72	-0.018	-0.018	-0.003
Net Change in Cash	-77.022	54.103	2.792	4.271	-0.219
Financing Cash Flow Items		-0.876	-0.876	-0.876
Total Cash Dividends Paid		0		0
Deferred Taxes	-0.288

Investor Name	Investor Type	Percent Outstanding	Shares Held	Shares change	Holdings Date	Turnover Rating
Opaleye Management Inc.	Hedge Fund	10.7503	3775000	0	2023-06-30	MED
Baum (Mark L)	Individual Investor	5.7561	2021261	5800	2023-08-14	LOW
The Vanguard Group, Inc.	Investment Advisor/Hedge Fund	4.7248	1659137	272811	2023-06-30	LOW
BlackRock Institutional Trust Company, N.A.	Investment Advisor	4.6632	1637499	1165249	2023-06-30	LOW
Morgan Stanley & Co. LLC	Research Firm	4.1425	1454651	728787	2023-06-30	MED
Braidwell LP	Hedge Fund	4.1365	1452538	0	2023-06-30	HIGH
Private Capital Management	Investment Advisor/Hedge Fund	3.2816	1152346	-13375	2023-06-30
Portolan Capital Management, L.L.C.	Investment Advisor/Hedge Fund	3.1297	1098999	26030	2023-06-30	HIGH
Renaissance Technologies LLC	Hedge Fund	2.5382	891312	-71300	2023-06-30	HIGH
Assenagon Asset Management S.A.	Investment Advisor	2.518	884208	81758	2023-06-30	HIGH
State Street Global Advisors (US)	Investment Advisor/Hedge Fund	1.6627	583873	485860	2023-06-30	LOW
Geode Capital Management, L.L.C.	Investment Advisor/Hedge Fund	1.5495	544121	276586	2023-06-30	LOW
Dimensional Fund Advisors, L.P.	Investment Advisor/Hedge Fund	1.5235	534976	92521	2023-06-30	LOW
Boll (Andrew R)	Individual Investor	1.5212	534169	210150	2023-07-18	MED
Driehaus Capital Management, LLC	Investment Advisor/Hedge Fund	1.3676	480237	184183	2023-06-30	MED
Invenire Capital, LLC	Investment Advisor	1.2923	453794	-60000	2022-09-30	LOW
Invictus Private Wealth, LLC	Investment Advisor	1.1393	400066	-108250	2023-09-30	LOW
Two Sigma Investments, LP	Hedge Fund	1.1274	395872	-188975	2023-06-30	HIGH
Ophir Asset Management Pty Ltd	Investment Advisor	1.01	354679	-83455	2023-06-30	HIGH
Wasatch Global Investors Inc	Investment Advisor/Hedge Fund	0.9765	342899	-7765	2023-06-30	LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Harrow Health, Inc. Company profile

About Harrow Health Inc

Harrow Health, Inc. is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. The Company holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The Company also owns royalty rights in four clinical stage drug candidates, which are being developed by Surface Ophthalmics and Melt Pharmaceuticals.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Harrow Health Inc revenues increased 48% to $72.5M. Net loss applicable to common stockholders increased from $3.4M to $18.5M. Revenues reflect Product sales, net increase of 43% to $69.1M, Other revenues increase from $392K to $3.4M. Higher net loss reflects Investment losses from Eton Pharmaceutic decrease from $3.3M (income) to $10.1M (expense), Selling.

Equity composition

Common stock, $.001 Par, 02/12, 50M auth., 1,991,508 issd. Insiders own approx. 27.50%. 02/12, 1-for-8 Reverse split. 1-for-5 reverse stock split.

Industry:

Pharmaceuticals (NEC)

102 Woodmont Blvd
Suite 610
NASHVILLE
TENNESSEE 37215
US

Income Statement

Annual
Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023